Site Overlay


In patients with atrial fibrillation who were unable to receive warfarin for any reason, the use of apixaban reduced the risk of stroke and systemic embolism when compared to aspirin. Study Rundown: Atrial fibrillation is a common arrhythmia that increases the risk of stroke and. AVERROES has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. AVERROES. Apixaban Versus ASA. To Reduce the Risk Of Stroke. Coordinated by Population Health Research institute. Hamilton, Ontario, Canada. Sponsors.

Author: Marn Nikobei
Country: Papua New Guinea
Language: English (Spanish)
Genre: Video
Published (Last): 28 October 2007
Pages: 333
PDF File Size: 16.63 Mb
ePub File Size: 12.87 Mb
ISBN: 303-3-54932-845-2
Downloads: 4313
Price: Free* [*Free Regsitration Required]
Uploader: Zoloshakar

Retrieved from ” http: Presented as apixaban vs. Assessment that INR could not or was unlikely to be measured at requested interval; 5. Avsrroes to editor Correspondence: In addition, patients could not be receiving VKA therapy, either because it had been demonstrated unsuitable in their case or because it was expected to be unsuitable.

Views Read View source View history.

AVERROES – Wiki Journal Club

Patients also needed to have at least one apxaban the following risk factors for stroke: Statistics presented where given by the authors. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: J Am Coll Cardiol ; ESC sub specialties communities.


In April the Data and Safety Monitoring Board recommended early study termination because of clear benefit in favor of apixaban.

Apixaban in Patients with Atrial Fibrillation. Usable articles Cardiology Neurology. The trial was terminated early given a treatment benefit with apixaban.

Dual therapy decreased rates of major vascular events at cost of increased major bleeding. Connolly SJ, et al. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. In patients with atrial fibrillation thought to be unsuitable candidates for anticoagulation with a vitamin K antagonist, apixaban signficantly reduced the risk of stroke and systemic embolism without increasing the risk of major bleeding or intracranial hemorrhage when compared to aspirin.

There were 11 intracranial bleeds on apixaban and 13 on aspirin apixaban 1. In patients with atrial fibrillation thought to be unsuitable for anticoagulation with a vitamin K antagonist, does apixaban reduce risk for stroke or systemic embolism when compared to aspirin? Read your latest personalised notifications Sign in No account xpixaban

Concurrent medications that could alter activity of VKAs; 8. Sign in to My ESC. Concurrent medications whose metabolism could be affected by VKAs; 9. To reduce the burden of cardiovascular disease. Its role in prevention of stroke in patients unsuitable for VKA therapy, but maintained on aspirin therapy, was unknown.


Navigation menu Personal tools Create account Log zverroes.

Other characteristics indicating risk of stroke too low to warrant treatment with VKAs; There were 44 1. Adverse event not related to bleeding during VKA therapy; 3.

Did you know that your browser is out of date? Yet, these proportions reflect the current underuse of VKAs in multiple registries. It has multiple theoretical benefits over VKA therapy including less intensive monitoring and fewer drug interactions.

The AVERROES Trial – Clinical Implications

Guidelines for the management of atrial fibrillation: Dabigatran versus warfarin in patients with atrial fibrillation. The reasons that VKA therapy was unsuitable for the patient had to be documented in the study case report forms.

There were 51 primary outcome events in those randomised to apixaban 1. All aaverroes reasons can be grouped in three broad aplxaban Based on the indirect comparison with ACTIVE A, one should conclude that apixaban is, at the time of writing, the best alternative to aspirin ever found in patients deemed unsuitable for VKAs. Analyses are to time of first event.